Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study

The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Treatment-experien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	AIDS research and therapy 2020-07, Vol.17 (1), p.45-7, Article 45
Hauptverfasser:	Suárez-García, Inés, Moreno, Cristina, Ruiz-Algueró, Marta, Pérez-Elías, María Jesús, Navarro, Marta, Díez Martínez, Marcos, Viciana, Pompeyo, Pérez-Martínez, Laura, Górgolas, Miguel, Amador, Concha, de Zárraga, Miguel Alberto, Jarrín, Inma
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adult AIDS Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Cobicistat - therapeutic use Cohort analysis Cohort studies Darunavir Darunavir - therapeutic use Drug dosages Drug resistance Drug Therapy, Combination - standards Emtricitabine Emtricitabine - therapeutic use Female Highly active antiretroviral therapy HIV HIV infection HIV Infections - drug therapy HIV-1 - drug effects Human immunodeficiency virus Humans Male Middle Aged Patients Quinolones - therapeutic use Spain Studies Tenofovir Tenofovir - therapeutic use Toxicity Treatment Outcome Viral Load - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014-2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL)
ISSN:	1742-6405 1742-6405
DOI:	10.1186/s12981-020-00302-2